BidaskClub upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday morning.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a hold rating to a buy rating and set a $46.00 target price on the stock in a research report on Wednesday, January 10th. B. Riley increased their target price on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the company a buy rating in a research report on Thursday, December 28th. Janney Montgomery Scott upgraded Supernus Pharmaceuticals from a neutral rating to a buy rating and set a $47.00 target price on the stock in a research report on Monday, December 4th. ValuEngine upgraded Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, March 1st. Finally, Berenberg Bank initiated coverage on Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a buy rating and a $66.00 target price on the stock. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Supernus Pharmaceuticals currently has an average rating of Buy and an average price target of $51.36.
SUPN stock opened at $44.45 on Wednesday. Supernus Pharmaceuticals has a 52-week low of $28.46 and a 52-week high of $50.04. The stock has a market capitalization of $2,270.21, a P/E ratio of 41.93 and a beta of 1.07.
In related news, VP Victor Vaughn sold 15,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total value of $630,600.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 165,750 shares of company stock valued at $7,133,973. 6.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Nationwide Fund Advisors raised its stake in Supernus Pharmaceuticals by 240.1% in the 3rd quarter. Nationwide Fund Advisors now owns 242,691 shares of the specialty pharmaceutical company’s stock valued at $9,708,000 after purchasing an additional 171,341 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth $2,255,000. BNP Paribas Arbitrage SA increased its stake in shares of Supernus Pharmaceuticals by 73.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 26,072 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after acquiring an additional 11,038 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Supernus Pharmaceuticals by 61.3% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 19,080 shares of the specialty pharmaceutical company’s stock worth $763,000 after acquiring an additional 7,250 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth $522,000. 96.21% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals (SUPN) Upgraded by BidaskClub to Strong-Buy” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3298057/supernus-pharmaceuticals-supn-upgraded-by-bidaskclub-to-strong-buy.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.